Literature DB >> 32916062

Estimated Population-Level Impact of Using a Six-Week Regimen of Daily Rifapentine to Treat Latent Tuberculosis Infection in the United States.

Sourya Shrestha1, Andrea Parriott2, Nicolas A Menzies3, Priya B Shete2, Andrew N Hill4, Suzanne M Marks4, David W Dowdy1.   

Abstract

Entities:  

Year:  2020        PMID： 32916062      PMCID： PMC7923126          DOI： 10.1513/AnnalsATS.202005-574RL

Source DB:  PubMed          Journal:  Ann Am Thorac Soc        ISSN： 2325-6621


× No keyword cloud information.
  13 in total

1.  Cost-effectiveness of a 12-dose regimen for treating latent tuberculous infection in the United States.

Authors:  D Shepardson; S M Marks; H Chesson; A Kerrigan; D P Holland; N Scott; X Tian; A S Borisov; N Shang; C M Heilig; T R Sterling; M E Villarino; W R Mac Kenzie
Journal:  Int J Tuberc Lung Dis       Date:  2013-12       Impact factor: 2.373

2.  Four Months of Rifampin or Nine Months of Isoniazid for Latent Tuberculosis in Adults.

Authors:  Dick Menzies; Menonli Adjobimey; Rovina Ruslami; Anete Trajman; Oumou Sow; Heejin Kim; Joseph Obeng Baah; Guy B Marks; Richard Long; Vernon Hoeppner; Kevin Elwood; Hamdan Al-Jahdali; Martin Gninafon; Lika Apriani; Raspati C Koesoemadinata; Afranio Kritski; Valeria Rolla; Boubacar Bah; Alioune Camara; Isaac Boakye; Victoria J Cook; Hazel Goldberg; Chantal Valiquette; Karen Hornby; Marie-Josée Dion; Pei-Zhi Li; Philip C Hill; Kevin Schwartzman; Andrea Benedetti
Journal:  N Engl J Med       Date:  2018-08-02       Impact factor: 91.245

Review 3.  Controlled chemoprophylaxis trials in tuberculosis. A general review.

Authors:  S H Ferebee
Journal:  Bibl Tuberc       Date:  1970

4.  Impact and Effectiveness of State-Level Tuberculosis Interventions in California, Florida, New York, and Texas: A Model-Based Analysis.

Authors:  Sourya Shrestha; Sarah Cherng; Andrew N Hill; Sue Reynolds; Jennifer Flood; Pennan M Barry; Adam Readhead; Margaret Oxtoby; Michael Lauzardo; Tom Privett; Suzanne M Marks; David W Dowdy
Journal:  Am J Epidemiol       Date:  2019-09-01       Impact factor: 4.897

5.  Efficacy of various durations of isoniazid preventive therapy for tuberculosis: five years of follow-up in the IUAT trial. International Union Against Tuberculosis Committee on Prophylaxis.

Authors: 
Journal:  Bull World Health Organ       Date:  1982       Impact factor: 9.408

6.  Outlook for tuberculosis elimination in California: An individual-based stochastic model.

Authors:  Alex J Goodell; Priya B Shete; Rick Vreman; Devon McCabe; Travis C Porco; Pennan M Barry; Jennifer Flood; Suzanne M Marks; Andrew Hill; Adithya Cattamanchi; James G Kahn
Journal:  PLoS One       Date:  2019-04-09       Impact factor: 3.240

7.  Guidelines for the Treatment of Latent Tuberculosis Infection: Recommendations from the National Tuberculosis Controllers Association and CDC, 2020.

Authors:  Timothy R Sterling; Gibril Njie; Dominik Zenner; David L Cohn; Randall Reves; Amina Ahmed; Dick Menzies; C Robert Horsburgh; Charles M Crane; Marcos Burgos; Philip LoBue; Carla A Winston; Robert Belknap
Journal:  MMWR Recomm Rep       Date:  2020-02-14

8.  Comparative Modeling of Tuberculosis Epidemiology and Policy Outcomes in California.

Authors:  Nicolas A Menzies; Andrea Parriott; Sourya Shrestha; David W Dowdy; Ted Cohen; Joshua A Salomon; Suzanne M Marks; Andrew N Hill; Carla A Winston; Garrett R Asay; Pennan Barry; Adam Readhead; Jennifer Flood; James G Kahn; Priya B Shete
Journal:  Am J Respir Crit Care Med       Date:  2020-02-01       Impact factor: 21.405

9.  Tuberculosis Infection in the United States: Prevalence Estimates from the National Health and Nutrition Examination Survey, 2011-2012.

Authors:  Roque Miramontes; Andrew N Hill; Rachel S Yelk Woodruff; Lauren A Lambert; Thomas R Navin; Kenneth G Castro; Philip A LoBue
Journal:  PLoS One       Date:  2015-11-04       Impact factor: 3.240

10.  Simple Estimates for Local Prevalence of Latent Tuberculosis Infection, United States, 2011-2015.

Authors:  Maryam B Haddad; Kala M Raz; Timothy L Lash; Andrew N Hill; J Steve Kammerer; Carla A Winston; Kenneth G Castro; Neel R Gandhi; Thomas R Navin
Journal:  Emerg Infect Dis       Date:  2018-10       Impact factor: 6.883
View more
  1 in total

1.  The Health and Economic Benefits of Tests That Predict Future Progression to Tuberculosis Disease.

Authors:  Nicolas A Menzies; Sourya Shrestha; Andrea Parriott; Suzanne M Marks; Andrew N Hill; David W Dowdy; Priya B Shete; Ted Cohen; Joshua A Salomon
Journal:  Epidemiology       Date:  2022-01-01       Impact factor: 4.822
  1 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.